Abstract: The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.
Type:
Grant
Filed:
May 4, 2018
Date of Patent:
December 21, 2021
Assignee:
ALLAKOS INC.
Inventors:
Christopher Robert Bebbington, Bradford Andrew Youngblood, Nenad Tomasevic
Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
Type:
Grant
Filed:
December 9, 2014
Date of Patent:
January 17, 2017
Assignee:
ALLAKOS INC.
Inventors:
Christopher R. Bebbington, Rustom Falahati, Carolina Rita Sousa Fernandes, David John Matthews, Nenad Tomasevic, Jason Williams, John Leung
Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
Type:
Application
Filed:
December 9, 2014
Publication date:
July 23, 2015
Applicant:
ALLAKOS INC.
Inventors:
CHRISTOPHER R. BEBBINGTON, RUSTOM FALAHATI, CAROLINA RITA SOUSA FERNANDES, DAVID JOHN MATTHEWS, NENAD TOMASEVIC, JASON WILLIAMS, JOHN LEUNG
© 2025 Justia
